1974
Treatment of malignant melanoma with methyl CCNU
Young R, Canellos G, Chabner B, Schein P, Brereton H, DeVita V. Treatment of malignant melanoma with methyl CCNU. Clinical Pharmacology & Therapeutics 1974, 15: 617-622. PMID: 4601745, DOI: 10.1002/cpt1974156617.Peer-Reviewed Original Research
1972
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Bagley C, Canellos G, Young R, Gallelli J, Devita V. Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemotherapy Reports 1972, 56: 387-91. PMID: 19051499.Peer-Reviewed Original ResearchConceptsClinical trialsDose-limiting toxic effectPhase II trialBone marrow toxicityConsecutive daily injectionsTime of onsetDegree of severitySevere nauseaII trialObjective responseDaily injectionsMarrow toxicityPatientsTrialsToxic effectsToxicityNauseaVomitingPainLymphomaMelanomaTumorsLymphosarcomaAdministrationDose
1970
CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO
Young R, DeVita V. CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO. Cell Proliferation 1970, 3: 285-290. PMID: 5523056, DOI: 10.1111/j.1365-2184.1970.tb00273.x.Peer-Reviewed Original Research
1966
Preliminary clinical studies with ibenzmethyzin
DeVita V, Serpick A, Carbone P. Preliminary clinical studies with ibenzmethyzin. Clinical Pharmacology & Therapeutics 1966, 7: 542-546. PMID: 5939977, DOI: 10.1002/cpt196674542.Peer-Reviewed Original ResearchConceptsBone marrow depressionDaily oral dosesBone marrow toxicityPreliminary clinical studyMarrow depressionHodgkin's diseaseOral dosesWeekly injectionsMarrow toxicityAdverse reactionsMalignant melanomaOral administrationClinical studiesNeoplastic diseasePatientsAntitumor activityDiseaseNauseaVomitingSomnolenceNeurologicMelanomaAtaxiaAdministrationDose